SYDNEY: CardieX announced that the Company’s ATCOR medical device division has officially partnered with Chinese healthcare industry Limited as its new national distributor in China.

Auden will further commercialization efforts for ATCOR’s non-invasive central blood pressure (NcBP) monitoring technology in public and private hospital channels as well as sports medicine institutions in the Greater China region, including mainland China, Hong Kong and Macau.

With substantial experience in clinical education and strategic marketing of cardiovascular health technologies, Auden has made significant inroads into top-tier Level 3A hospitals as a professional medical technology distributor with strong cardiology focus.

Covering the Chinese healthcare industry since 2009, Auden has represented several leading medical technology innovators in hypertension, diabetes, and sleep health, including Omron Healthcare and Itamar Medical.

Some of the medical institutions that Auden collaborates with include: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Fuwai Hospital, People’s Liberation Army General Hospital, Peking University First Hospital, Peking University People’s Hospital, Peking University Third Hospital, Beijing Chaoyang Hospital, First Affiliated Hospital of Sun Yat-sen University, Southern Medical University Nanfang Hospital, Xiangya Hospital, and many others across China.

With this new partnership, the founders of Auden are seeking to further their cardiology distribution business with a focused commercial strategy around ATCOR’s XCEL system as its primary portfolio offering.

Commenting on the partnership, CardieX’s VP of Corporate Development ZiHan Lin stated: “With this renewed focus on XCEL and prior experience in other chronic illness technologies, we believe Auden is well-positioned to drive ATCOR’s long-term growth plans in the Chinese market. This also represents a material step forward as we look to broaden our market penetration in China for our roadmap of new products and services”.

Garry Zhang, CEO of Auden commented: “ATCOR provides a personalized and precise solution for hypertensive patients. Through earnest collaboration between Auden and ATCOR, I believe we can dramatically increase the adoption of ATCOR’s technology, especially due to its strategic alignment with China’s nationwide advancement of the “Healthy China 2030” initiative”.